Theralase Technologies Inc (TSX-V:TLT, OTCQB:TLTFF) CEO Roger Dumoulin-White joined Proactive to discuss the latest developments for the company's lead drug, Ruvidar, which is targeting non-muscle invasive bladder cancer.
Dumoulin-White shared updates from their ongoing Phase 2 registration study, in which Theralase’s treatment is achieving impressive results, with three out of five patients becoming cancer-free after just one treatment session.
Proactive: Could you give us an update on how Theralase is progressing with your lead cancer treatment?
Roger Dumoulin-White: Yes, sure. Our lead drug is Ruvidar, which targets non-muscle invasive bladder cancer. We're currently in a Phase 2 registration study. We've enrolled 75 patients so far, and we've evaluated 68 of them at the 90-day mark.
What are the key results you're seeing in these patients?
We're showing a complete response rate for patients of 60% at any point in time, which is quite remarkable. That means three out of five patients are becoming cancer-free after just one treatment.
That’s impressive. How long are these patients staying cancer-free?
About a third of the patients remain cancer-free for three years or more. So, we're not only seeing a strong initial response but also a durable one.
What's next in the study? Are there more patients to enroll?
Yes, we plan to enroll between 75 to 100 patients in total. The data needs to reach statistical significance, so we'll continue enrolling until we hit that number. We're also preparing for more interim data releases in the coming months.
It sounds like you’re on track. What does the future look like for Theralase with this drug?
We’re very optimistic. If the final data aligns with what we’re seeing so far, Ruvidar could offer a significant new option for bladder cancer patients. Our aim is to get this therapy approved and into the hands of doctors to help patients as soon as possible.
Quotes have been lightly edited for clarity and style